These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 8525651)

  • 21. Differential modulation of LAK and ADCC functions of natural killer cells from AK-5 tumor-bearing rats by IL-2, IL-12 and IFN-gamma.
    Muralikrishna K; Varalakshmi C; Khar A
    Cytokines Cell Mol Ther; 1997 Mar; 3(1):51-8. PubMed ID: 9287244
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Murine studies using polyethylene glycol-modified recombinant human interleukin 2 (PEG-IL-2): antitumor effects of PEG-IL2 alone and in combination with adoptive cellular transfer.
    Yang JC; Schwarz SL; Perry-Lalley DM; Rosenberg SA
    Lymphokine Cytokine Res; 1991 Dec; 10(6):475-80. PubMed ID: 1804310
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Potent graft antitumor effect in natural killer-resistant disseminated tumors by transplantation of interleukin 2-activated syngeneic bone marrow in mice.
    Agah R; Malloy B; Kerner M; Girgis E; Bean P; Twomey P; Mazumder A
    Cancer Res; 1989 Nov; 49(21):5959-63. PubMed ID: 2790810
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Adoptive immunotherapeutic treatments with interleukin 2 and lymphocytes in a mouse colonic adenocarcinoma model.
    Rodolfo M; Salvi C; Bassi C; Sensi M; Parmiani G
    Ann Ist Super Sanita; 1990; 26(3-4):423-32. PubMed ID: 2091504
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Interleukin-12 gene therapy of a weakly immunogenic mouse mammary carcinoma results in reduction of spontaneous lung metastases via a T-cell-independent mechanism.
    Rakhmilevich AL; Janssen K; Hao Z; Sondel PM; Yang NS
    Cancer Gene Ther; 2000 Jun; 7(6):826-38. PubMed ID: 10880012
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Enhanced antitumor immune responses of IL-2 gene-modified tumor vaccine by combination with IL-1 and low dose cyclophosphamide.
    Cao X; Zhang W; Wan T; Yu Y; Tao Q; Wang J
    J Exp Clin Cancer Res; 1999 Jun; 18(2):173-9. PubMed ID: 10464704
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of combined therapy with lymphokine-activated killer cells, interleukin 2 and specific monoclonal antibody on established B16 melanoma lung metastases.
    Eisenthal A; Cameron RB; Uppenkamp I; Rosenberg SA
    Cancer Res; 1988 Dec; 48(24 Pt 1):7140-5. PubMed ID: 3263900
    [TBL] [Abstract][Full Text] [Related]  

  • 28. In vivo antitumor activity of interleukin 21 mediated by natural killer cells.
    Wang G; Tschoi M; Spolski R; Lou Y; Ozaki K; Feng C; Kim G; Leonard WJ; Hwu P
    Cancer Res; 2003 Dec; 63(24):9016-22. PubMed ID: 14695220
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Targeting of products of genes to tumor sites using adoptively transferred A-NK and T-LAK cells.
    Goding S; Yang Q; Mi Z; Robbins PD; Basse PH
    Cancer Gene Ther; 2007 May; 14(5):441-50. PubMed ID: 17273184
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo.
    Mulé JJ; Shu S; Rosenberg SA
    J Immunol; 1985 Jul; 135(1):646-52. PubMed ID: 3889158
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluation of combined vaccinia virus-mediated antitumor gene therapy with p53, IL-2, and IL-12 in a glioma model.
    Chen B; Timiryasova TM; Andres ML; Kajioka EH; Dutta-Roy R; Gridley DS; Fodor I
    Cancer Gene Ther; 2000 Nov; 7(11):1437-47. PubMed ID: 11129286
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Systemic administration of cellular IL-10 induces an effective, specific, and long-lived immune response against established tumors in mice.
    Berman RM; Suzuki T; Tahara H; Robbins PD; Narula SK; Lotze MT
    J Immunol; 1996 Jul; 157(1):231-8. PubMed ID: 8683120
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tumor growth suppression by a mouse/human chimeric anti-CEA antibody and lymphokine-activated killer cells in vitro and in SCID mouse xenograft model.
    Senba T; Kuroki M; Arakawa F; Yamamoto T; Kuwahara M; Haruno M; Ikeda S; Matsuoka Y
    Anticancer Res; 1998; 18(1A):17-24. PubMed ID: 9568050
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Successful immunotherapy of murine experimental hepatic metastases with lymphokine-activated killer cells and recombinant interleukin 2.
    Lafreniere R; Rosenberg SA
    Cancer Res; 1985 Aug; 45(8):3735-41. PubMed ID: 3893689
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Suppression of graft-versus-host disease and amplification of graft-versus-tumor effects by activated natural killer cells after allogeneic bone marrow transplantation.
    Asai O; Longo DL; Tian ZG; Hornung RL; Taub DD; Ruscetti FW; Murphy WJ
    J Clin Invest; 1998 May; 101(9):1835-42. PubMed ID: 9576746
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Synergistic effect of intratumoral IL-12 and TNF-alpha microspheres: systemic anti-tumor immunity is mediated by both CD8+ CTL and NK cells.
    Sabel MS; Arora A; Su G; Mathiowitz E; Reineke JJ; Chang AE
    Surgery; 2007 Nov; 142(5):749-60. PubMed ID: 17981196
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Augmentation of interleukin-2 immunotherapeutic effects by lymphokine-activated killer cells and allogeneic stimulation in murine tumor cells.
    Eggermont AM; Steller EP; Ottow RT; Matthews W; Sugarbaker PH
    J Natl Cancer Inst; 1987 Nov; 79(5):983-90. PubMed ID: 3500357
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immunotherapy of cancer with lymphokine-activated killer cells and recombinant interleukin-2.
    Rosenberg SA; Mulé JJ
    Surgery; 1985 Sep; 98(3):437-44. PubMed ID: 3898451
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Adenovirus-interleukin-12-mediated tumor regression in a murine hepatocellular carcinoma model is not dependent on CD1-restricted natural killer T cells.
    Andrews KJ; Ribas A; Butterfield LH; Vollmer CM; Eilber FC; Dissette VB; Nelson SD; Shintaku P; Mekhoubad S; Nakayama T; Taniguchi M; Glaspy JA; McBride WH; Economou JS
    Cancer Res; 2000 Nov; 60(22):6457-64. PubMed ID: 11103813
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Synergistic in vivo antitumor effect of the histone deacetylase inhibitor MS-275 in combination with interleukin 2 in a murine model of renal cell carcinoma.
    Kato Y; Yoshimura K; Shin T; Verheul H; Hammers H; Sanni TB; Salumbides BC; Van Erp K; Schulick R; Pili R
    Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4538-46. PubMed ID: 17671140
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.